GLP-1 agonist / GIP antagonist
ALV-100
2 trials in this molecule. Source: ClinicalTrials.gov, as of November 5, 2026.
Trials
2
Ongoing
2
Recruiting
1
Completed
0
Sites
23
Countries
1
Endpoints
20
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
1
Phase 2
1
Trials by status
Recruiting
1
Active, not recruiting
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
9
Weight & body composition
4
Glycemic / diabetes
2
Patient-reported / QoL
2
Other (unclassified)
2
Cardiometabolic biomarkers
1
Top 20 metrics across this asset's endpoints
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
2 of 2
| Asset / Population | Eligibility highlight | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| PRESERVEStudy to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss | ALV-100 Adults, Obesity / overweight | BMI ≥23 | Ph 2 | Recruiting | 20 | Aug 2027 | - | |
| NCT07399678Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D | ALV-100 Obesity / overweight, Type 2 diabetes | BMI 27-39.9 | Ph 1 | Active, not recruiting | 3 | Oct 2027 | - |
Showing 1-2 of 2 trials